

Company Profile



Angelini
Pharma

Part of Angelini Industries

ANGELINI PHARMA

Angelini Pharma, part of Angelini Industries, is an international pharmaceutical company dedicated to researching, developing, and marketing health solutions that significantly improve people's quality of life. The company focuses mainly on **Brain Health** (including Mental Health and Epilepsy), **Specialty and Primary Care**, and **Consumer Healthcare**.

Angelini Pharma is a fully integrated company with extensive and well-recognized **research and development programs, world-class production facilities, and international commercialization** activities of active ingredients and leading drugs in many market sectors.

It operates directly in **20 countries** and, through strategic partnerships with leading international pharmaceutical companies, markets its products in 70 countries across Europe, North America, South America, and Asia.

Angelini Pharma benefits from the dedication of over **3,000 employees** in various strategic areas, including 800+ in manufacturing, 1,000 in sales, and nearly 150 in R&D—key sectors driving innovation and competitiveness.

Notably, 51% of its workforce is female, and 49% is male. The company has achieved **UNI/PdR 125:2022 Certification** for gender equality and has been named a **Top Employer** for four consecutive years, reflecting its focus on employee well-being and professional development.

Employee well-being is one of the four pillars of Angelini Pharma's **ESG strategy**, which encompasses **Planet, People, Patients** and **Communities**, and Ecosystems. This comprehensive approach reflects a commitment to responsible business practices aimed at building a more sustainable future for current and future generations. Aligned with this vision, the company strives to generate social and environmental value by supporting health and well-being, fostering responsible innovation, and minimizing environmental impact across its entire value chain.

ANGELINI PHARMA BY THE NUMBERS



THERAPEUTICS AREAS

BRAIN HEALTH

For over 50 years, Angelini Pharma has been dedicated to improving the lives of patients with mental health disorders and, more recently, neurological conditions such as epilepsy. The company consistently invests in research to develop new products and ensure their effectiveness while advocating against the stigma surrounding these conditions.



Mental Health

In the field of mental health, Angelini Pharma provides treatments for depression, bipolar disorder, and schizophrenia, adopting a holistic approach that integrates innovative pharmaceutical solutions with support beyond the medicine, addressing biological, social, and environmental factors.



Epilepsy

For epilepsy, Angelini Pharma holds exclusive licensing rights to cenobamate in the EU and other EEA countries, an innovative treatment for focal-onset seizures in adults with drug-resistant epilepsy. The introduction of cenobamate in Italy in 2022 marked a significant step toward improving the quality of life for epilepsy patients.

SPECIALTY AND PRIMARY CARE

Angelini Pharma offers integrated therapies, providing a comprehensive range of solutions for **pain management**, fever, and **anti-infectives**, acting as a trusted partner for healthcare professionals and a reliable patient choice.



Pain

For Pain Management, Angelini Pharma has a complete portfolio of prescription drugs that covers all stages of the analgesic ladder, offering tailored solutions for different patient needs.



Fever

For Fever Management, Angelini Pharma has a longstanding expertise in managing cold symptoms in children and adults. The company conducts annual training programs for pediatricians, focusing on therapeutic appropriateness and management of fever in children, and promotes a holistic approach that also considers the general well-being of the pediatric patient.



Anti-infectives

In the area of Anti-Infectives, Angelini Pharma is committed to tackling antibiotic resistance, promoting rational drug use, and running awareness programs to improve practices.

CONSUMER HEALTHCARE

In the Consumer Healthcare sector, Angelini Pharma holds a leadership role thanks to a wide range of over the counter (OTC) medications and non-pharmaceutical products designed to meet the needs of patients of all ages. The company is present in the areas of pain and cold diseases and disinfection, as well as in the fields of **dietary supplements** and **personal hygiene and care**.



Pain and Cold Diseases

In pain and cold diseases, Angelini Pharma offers reference products like Moment[®], a leader in treating mild to moderate pain, ThermaCare[®], heat wraps for the relief of musculoskeletal and menstrual pain, and Tantum Verde[®], which is indicated for treating oral and throat irritations and inflammation. Internationally, the company expands its portfolio with products like Boxagrippal[®], available in Austria and Germany, Juanola[®] in Spain, and Erdomed[®], widespread in Eastern European markets, offering a broad range of solutions for respiratory well-being.



Disinfection

In the disinfection sector, Angelini Pharma is synonymous with safety and hygiene, and the historic brand Amuchina[®] has been recognized for its reliability for over a century. During the COVID-19 pandemic, Amuchina further strengthened its leadership role in the sector, becoming an indispensable ally for public health.



Hygiene and Personal Care

For personal hygiene and care, the company stands out with brands like Tantum Rosa[®], which is dedicated to women's intimate well-being, and Infasil[®], which is synonymous with daily protection for the whole family.



Dietary Supplements

Angelini Pharma is also active in the dietary supplement sector with brands like Acutil[®] and Energya[®], which help promote cognitive function, support energy metabolism, and help combat fatigue.

RESEARCH AND DEVELOPMENT

Angelini Pharma's R&D has a rich legacy of discovering and developing key active ingredients, such as **trazodone** and **benzidamine**. Today, its research focuses on **Brain Health** - particularly mental health and epilepsy - and **Consumer Health**.

In line with this commitment to Brain Health, the research and development pipeline includes three preclinical projects focused on epileptic syndromes. Additional research initiatives are currently under evaluation and are expected to expand the company's portfolio in the near future.

Today, Angelini Pharma is engaged in over **20 clinical studies**, both interventional and observational, involving **more than 3,500 patients** in various countries. While primarily focusing on Brain Health, particularly epilepsy and psychiatric disorders, the company continues to support its established portfolio, which includes OTC medications, prescription drugs, and non-pharmaceutical products like medical devices (ThermaCare®), biocides, and cosmetics, via the generation of additional data.

Angelini Pharma also collaborates with universities and centers of excellence nationally and internationally, recognizing the value of scientific collaborations as a fundamental lever for promoting innovation.



70+ years
of experience
in R&D

With expertise ranging from drug discovery to full development, registration, and life cycle Management of pharmaceutical products



~150
researchers

dedicated to developing new drugs and optimizing existing ones



300+
publications

in peer-reviewed scientific journals in the last 10 years.

PRODUCTION SITES

Angelini Pharma's production facilities are state-of-the-art in technology, comply with industry standards, and are environmentally sustainable, thanks to the use and integration of renewable sources. The sites include **Ancona** (Italy) for finished products, **Aprilia** (Italy) for raw materials, and **Casella** (Italy) for Amuchina-branded products. In **Barcelona** (Spain), the company produces dietary supplements like Pastillas Juanola, while in 2020, it acquired the Albany facility (Georgia, USA), a global supplier of ThermaCare® Headwrap.

All facilities employ the **most advanced technologies**, with automated control and supervision systems. Quality analysis and control are particularly important throughout the process, starting with raw materials.

ANCONA (Italy)

Total area: 177,000 m²

Number of employees: 610

Production capacity: 150 million packages/year

Produces solids, non-sterile liquids, semi-solids

CASELLA (Italy)

Total area: 17,000 m²

Number of employees: 40

Production capacity: 10 million liters/year

Produces disinfectant products under the Amuchina brand

APRILIA (Italy)

Total area: 70,000 m²

Number of employees: 200

Production capacity: 140,000 liters/year

Produces pharmaceutical active ingredients, advanced intermediates, and original Angelini raw materials.

ALBANY (Georgia, USA)

Total area: 20,000 m²

Number of employees: 126

Production capacity: >80 million packages/year

Produces ThermaCare heating wraps

BARCELONA (Spain)

Total area: 2,000 m²

Number of employees: 6

Production capacity: 3 million units of Juanola products

Produces Pastillas Juanola

GLOBAL PRESENCE

Angelini Pharma is a key player in health in Europe and beyond, developing and making innovative drugs and therapeutic solutions available globally, enabling people to improve their health and quality of life.

The company is headquartered in **Rome (Italy)** and is also present in **Spain, Portugal, Austria, Poland, the Czech Republic, Slovakia, Hungary, Germany, Romania, Bulgaria, Greece, Turkey, France**, the **UK, Sweden**, the **Netherlands, Switzerland, Russia**, and the **USA**. Strategic partnerships with international companies further expand Angelini Pharma's geographic presence. In line with its international expansion strategy, the company is growing in high-potential markets through targeted acquisitions and the development of existing structures.

Thanks to strategic alliances with leading pharmaceutical groups worldwide, **Angelini Pharma's products are distributed globally**. Among these, to name a few, are Trittico® (trazodone, antidepressant), Latuda® (lurasidone hydrochloride, antipsychotic), Tantum® (benzidamine, anti-inflammatory), Aulin® (nimesulide, anti-inflammatory analgesic), Vellofent® (fentanyl, analgesic), Xydalba® (dalbavancin, antibiotic), and Ontozry® (cenobamate, antiepileptic).




20 Countries

With a direct presence



70+ Countries

In which the products are marketed



40+

Commercial partners